Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omecamtiv Mecarbil Post-trial Access
NCT04464525Phase 3Withdrawn
- Sponsor
- Cytokinetics
- Start
- Dec 2020
- Primary completion
- Nov 2026
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of omecamtiv mecarbil in heart failure with reduced ejection fraction (HFrEF), sponsored by Cytokinetics. Planned start Dec 2020; status: withdrawn.
02
Drugs
omecamtiv mecarbil
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on NCT04464525.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04464525.